07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Abcodia, Cellmid deal

The companies partnered to validate midkine ( MDK ; MK ) as a biomarker for cancer diagnosis using Cellmid's MK-ELISA test. The deal covers testing of multiple cancer indications, but the partners will initially focus...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Cellmid, Fujikura Kasei Co. Ltd. deal

Cellmid said Fujikura exercised its option to license use of Cellmid's midkine ( MDK ; MK ) diagnostic antibodies on Fujikura's latex-based assay technology. Fujikura paid a ¥40 million ($398,800) fee. The companies will now...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

Cellmid, Fujikura Kasei Co. Ltd. deal

Fujikura received an option to license use of Cellmid's midkine ( MDK ; MK ) diagnostic antibodies on Fujikura's latex-based assay technology. Cellmid will receive an upfront fee and is eligible for an additional payment...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

Cellmid preclinical data

In a mouse model of diabetic nephropathy, 2 of Cellmid's MK-Abs significantly reduced glomerular sclerosis (<20% vs. 48%, p<0.01) and interstitial volume (12% vs. 35%, p<0.01) vs. untreated controls. Mice treated with the antibodies against...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Company News

Antitope, Cellmid deal

Antitope will use its EpiScreen and Composite Human Antibody technologies to humanize Cellmid's antibody against midkine ( MDK ; MK ). Preclinical testing in "several disease models" is expected to begin in 4Q11. Further terms...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

BioGenes GmbH, Cellmid sales and marketing update

Cellmid launched BioGenes' MK ELISA globally for research use to measure midkine ( MDK ; MK) in blood serum. The company said MDK has been found to correlate with cancer progression and malignancy. BioGenes GmbH...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Company News

Celera, Medical Therapies deal

Celera received an exclusive, worldwide license to Medical Therapies' midkine patent portfolio to develop and commercialize lung cancer diagnostics. Midkine is a heparin-binding growth factor. Medical Therapies is developing an ELISA test to detect midkine...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Company News

Ligand, Neurogen deal

Ligand will acquire Neurogen for about 4 million shares for a deal value of about $11 million based on Ligand's close of $2.76 on Aug. 21, the day before the deal was announced. Neurogen shareholders...
07:00 , Jun 4, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal disease Midkine (MDK) Studies in mice suggest that targeting MDK could help prevent hypertension and renal damage from chronic...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Archemix, Ribomic Inc. deal

The partners expanded a 2006 deal to give Ribomic a non-exclusive, worldwide license to use Archemix’s aptamer technology to develop aptamer therapeutics against undisclosed targets. The original deal gave Ribomic rights to use an aptamer...